

## North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 1<sup>st</sup> December 2021

### Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
Nil this month				
<b>2) New Requests</b>				
Nil this month				
<b>3) New formulations &amp; extensions to use</b>				
Nil this month				
<b>5) Products considered by NICE</b>				
<b>TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.

## DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA741: Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA744: Upadacitinib for treating moderate rheumatoid arthritis</b>	✓ <b>R</b>			The formulary will reflect the TAG – CCGs are the responsible commissioner.
<b>TA745: NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal)</b>	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>HST16: Givosiran for treating acute hepatic porphyria</b>	✓ <b>R</b>			The formulary will reflect the HST – NHS England is the responsible commissioner.
<b>6) Appeals against earlier decisions by the APC</b>				
None				
<b>7) Miscellaneous formulary decisions by the APC</b>				
Danazol 100mg and 200mg capsules	✓ <b>R</b>			Agreed to change from Amber SI/ to RED as now discontinued and there are no licensed products available Allows supply to continue via secondary care where necessary and appropriate, as advised by the MHRA.

#### DECISION SUMMARY

The following guidelines were presented to and approved at the December 2021 meeting of the APC:

- North Yorkshire and York Lipid Treatment Guidance
- NY&Y APC Topical testosterone for management of Low libido in menopausal women - Information sheet for Primary Care Prescribers and Patient Information Leaflet
- SC Levetiracetam in Palliative Care Guideline – amended to correct dosing error.

The following shared care guidelines were presented to and approved at the December 2021 meeting of the APC:

- TEWV Guanfacine Shared Care Guideline – reviewed November 2021

Other documents presented to and approved at the December 2021 meeting of the APC:

- Cardiovascular Formulary Chapter - the second chapter to be aligned across North Yorkshire and York.